Previous 10 | Next 10 |
According to data compiled by S&P Global Market Intelligence , genetics testing company Invitae 's (NYSE: NVTA) stock was up 6% in price week to date as of Friday before market open. Investors reacted quite positively to news of a new company partnership with a heavy hitter ...
Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, it's burned through cash -- and left investors wondering when and if the company can m...
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research PR Newswire – Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare can...
Invitae to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 PR Newswire SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Summary The introduction of new products and the further extension of reimbursement routes are projected to fuel CDNA growth. CDNA is renewing its emphasis on profitability after a widening loss caused a 14% share decline in August after the Q2 earnings release. CDNA is in a b...
Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...
Summary There is a high chance that the Illumina, Inc.-Grail deal would collapse after European regulators decide to block the acquisition. Without Grail, I believe Illumina will find it hard to maintain growth in light of disruptions in its end markets, namely the clinical gene t...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Invitae Appointed to National Quality Forum Committee on Quality Standards for Healthcare PR Newswire – First genetics testing company to sit on Forum – – Genetics perspective on committee will accelerate healthcare quality standards aligning wit...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...